Stock Market News
UDG slides on softer sales at Sharp
FTSE 250 listed firm UDG Healthcare saw a softer-than-expected start to the trading year after its second-largest business, Sharp, lowered its guidance for the remainder of its trading year.
UDG turned in a 4.4% lower revenue at Sharp of $118.6m over the six months leading to 31 March as the group's contract packaging division saw a 1.6% dip in operating profits, impacted by weaker demand for bottling from its US operations.
Sharp, which UDG pointed out would still deliver double-digit growth to its underlying operating profit in the second half but noted its full-year growth would slide to the mid-single digit area, down from its earlier estimates of low double-digit growth.
However, weaknesses at Sharp were somewhat offset by a 26% improvement in revenue from UDG's flagship business, Ashfield, which was boosted as a result of several recent acquisitions.
UDG reiterated its constant currency adjusted EPS growth of 18 to 21% after total revenue rose 17% to $568.7m.
Pre-tax profits jumped 19% to $63.2m.
UDG's chief executive, Brendan McAtamney said, "We remain confident that our strong market positions and the growing trend in the healthcare industry to outsource specialist activities on an international basis, leaves UDG well positioned for growth in FY18 and beyond."
As of 1100 BST, UDG shares had lost 5.48% to 880.50p.
UDG turned in a 4.4% lower revenue at Sharp of $118.6m over the six months leading to 31 March as the group's contract packaging division saw a 1.6% dip in operating profits, impacted by weaker demand for bottling from its US operations.
Sharp, which UDG pointed out would still deliver double-digit growth to its underlying operating profit in the second half but noted its full-year growth would slide to the mid-single digit area, down from its earlier estimates of low double-digit growth.
However, weaknesses at Sharp were somewhat offset by a 26% improvement in revenue from UDG's flagship business, Ashfield, which was boosted as a result of several recent acquisitions.
UDG reiterated its constant currency adjusted EPS growth of 18 to 21% after total revenue rose 17% to $568.7m.
Pre-tax profits jumped 19% to $63.2m.
UDG's chief executive, Brendan McAtamney said, "We remain confident that our strong market positions and the growing trend in the healthcare industry to outsource specialist activities on an international basis, leaves UDG well positioned for growth in FY18 and beyond."
As of 1100 BST, UDG shares had lost 5.48% to 880.50p.
Related share prices |
---|
UDG Healthcare Public Limited Company (UDG) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price